Minuscule risk of blood clots with Covishield, no clots yet with Covaxin: Expert panel

The risk factor discovered by the committee in India is lower than the four cases per million found among those given Astrazeneca jabs in the UK.

Published: 17th May 2021 03:13 PM  |   Last Updated: 09th June 2021 05:25 PM   |  A+A-

Covishield vaccine (L) and Covaxin (R)

Covishield vaccine (L) and Covaxin (R) (Photos | EPS)

By Express News Service

NEW DELHI: A very minuscule but definitive risk of thromboembolic (blood clot) events -- 0.61 cases per million vaccinations -- has been seen among those administered the Covishield vaccine in India, the National Adverse Events Following Immunisation (AEFI) committee has said in a report to the Ministry of Health and Family Welfare.

The data is based on an in-depth case review of 498 out of 700 serious and severe events following the administration of over 7.5 crore Covid vaccine doses in India till April 3, by the national adverse event following immunisation committee.

The report by the AEFI panel showed that a total of 26 thromboembolic events were found out of the 498 cases, from the total 700 serious and severe adverse events, that have been examined in detail so far. 

The committee has submitted its report to the Union Ministry of Health. “AEFI data in India showed that there is a very minuscule but definitive risk of thromboembolic events (formation of a clot in a blood vessel that might also break loose and carried by the blood stream to plug another vessel),” said the  ministry in a statement.  

It, however, did not reveal how many people had died due to this complication in India.

The reporting rate of these events in India is around 0.61 per million doses, which is much lower than the 4 cases per million reported by the UK’s regulator Medical and Health Regulatory Authority while Germany has reported 10 events per million doses, the government said.

There were no potential thromboembolic events reported following administration of Covaxin vaccine, the analysis by the AEFI committee has shown.

Till April 3, 75,435,381 vaccine doses had been administered in India -- 68,650,819 doses of Covishield and 6,784,562 doses of Covaxin.

Of these, 65,944,106 were first doses and 9,491,275 second doses. Since the Covid vaccination drive was initiated, more than 23,000 adverse events were reported through the CoWIN platform reported from 684 of the 753 districts of the country.

Of these, only 700 cases or 9.3 cases  per million doses administered were reported to be of a serious and severe nature, according to the AEFI committee.

ALSO READ | Senior virologist Shahid Jameel quits as Chief Advisor to Centre's Covid genome surveillance project

The panel has underscored that thromboembolic events keep occurring in the general population as background and scientific literature suggests that this risk is almost 70% less in persons of South and South East Asian descent in comparison to those from European descent.

The government, however, insisted that Covishield continues to have a definite positive benefit risk profile with tremendous potential to prevent infections and reduce Covid deaths.

The Health Ministry, it said, is continuously monitoring the safety of all Covid vaccines and is promoting reporting of suspected adverse events.

Following the findings of the committee, separate advisories will be issued to healthcare workers and vaccine beneficiaries to make them aware of suspected thromboembolic symptoms occurring within 20 days after receiving any vaccine, mainly particularly Covishield, and report preferably to the health facility where the vaccine was administered.

The development comes following persistent demands by public health experts and activists to release data on serious adverse events since Covid vaccination drive was started in the country in mid-January.

Signs and symptoms that may suggest possible blood clot event following vaccination:

  • Breathlessness
  • Pain in chest
  • Pain in limbs or pain on pressing limbs or swelling in limbs,
  • Multiple, pinhead size red spots or bruising of skin in an area beyond the injection site,
  • Persistent abdominal pain with or without vomiting,
  • Seizures in the absence of previous history of seizures with or without vomiting,
  • Severe and persistent headache with or without vomiting (in the absence of previous history of migraine or chronic headache),
  • Weakness or paralysis of limbs or any particular side or part of the body including face,
  • Persistent vomiting without any obvious reason,
  • Blurred vision or pain in eyes or having double vision,
  • Change in mental status or having confusion or depressed level of consciousness,
  • Any other symptom or health condition which is of concern to the recipient or the family.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp